L. Todd Edwards compensation by year
Arcutis Biotherapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $131,254 | $516,419 | $535,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $334,800 | $679,120 | $752,950 |
| Option awards | $938,855 | $452,117 | $1,380,182 |
| Non-equity incentive | $241,883 | $300,311 | $334,376 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $11,055 | $17,178 | $27,829 |
| Total | $1,657,847 | $1,965,145 | $3,030,337 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcutis Biotherapeutics, Inc. DEF 14A filed April 21, 2026, accession 0001787306-26-000028, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Arcutis Biotherapeutics, Inc. filed document, accession 0001787306-26-000028. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 38,000 | $1,103,520 | — |
| RSU | 30,000 | $871,200 | — |
| RSU | 21,000 | $609,840 | — |
| RSU | 17,000 | $493,680 | — |
| Option | 34,937 | — | $13.69 |
| Option | 91,667 | — | $3.64 |
| Option | 80,437 | — | $13.69 |
| Option | 110,000 | — | $5.58 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arcutis Biotherapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Arcutis Biotherapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Resignation for good reason, no change in control | $401,250 | $0 | $23,901 | $425,151 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
| Change in control and involuntary termination | $535,000 | $9,758,173 | $31,868 | $10,592,541 |
| Death | $0 | $0 | $0 | $0 |
| Disability | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in Arcutis Biotherapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Arcutis Biotherapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Todd Franklin Watanabe | President and Chief Executive Officer | $7,223,065 |
| L. Todd Edwards · this page | Executive Vice President and Chief Commercial Officer | $3,030,337 |
| Patrick Burnett | Executive Vice President and Chief Medical Officer | $3,016,508 |
| Masaru Matsuda | Executive Vice President, Chief Legal Officer and Corporate Secretary | $2,118,203 |
| David Topper | Former Chief Financial Officer | $1,946,733 |
| Latha Vairavan | Senior Vice President and Chief Financial Officer | $1,924,780 |
L. Todd Edwards's compensation dossier, Arcutis Biotherapeutics
You have read L. Todd Edwards's totals and holdings. The dossier adds each equity grant Arcutis Biotherapeutics disclosed for L. Todd Edwards and Arcutis Biotherapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Arcutis Biotherapeutics compensation record
free company briefThis page is one person within Arcutis Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Arcutis Biotherapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arcutis Biotherapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcutis Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ARQT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.